Objectives

This article aims to review the scientific evidence on the use of cariprazine in the treatment of negative symptoms and other domains of psychopathology.

Literature review

Treatment outcomes in schizophrenia remain suboptimal for many patients. Addressing specific symptom domains beyond the general symptomatology of schizophrenia may lead to significant functional improvement and substantially enhance the quality of life for both patients and caregivers.

Conclusions

Cariprazine, a partial agonist of dopamine D2/D3 receptors, has shown efficacy across multiple symptom domains in clinical trials, particularly in addressing negative symptoms. It appears to be a promising therapeutic option for certain patient groups. However, further research and robust scientific evidence are needed to confirm its effectiveness across broader contexts.